Pricing Log in Create free account
Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue
+268.4%
EPS
+73.8%
Free cash flow
+81.1%
Total debt
+0.27%

Quarter to September 2026, against a year earlier

111.15 2.39 +2.20%
Market cap
$23.9B
P/E
0.0×
Fwd P/E
−64.6×
Dividend yield
—
F-score
4/9
Altman Z
9.29
Beneish M
−1.90
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insmed, Inc. (INSM) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Insmed, Inc. (INSM) trades at a EV/Sales of 15.4×. Over the past ten years it has ranged from 0.0× (March 2019) to 98.1× (December 2025); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 56.1× 81.32%
FY2024 30.9× 104.29%
FY2023 15.1× 56.24%
FY2022 9.7× (37.66%)
FY2021 15.5× (17.62%)
FY2020 18.9× 35.48%
FY2019 13.9× —
FY2018 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 16.2× (19.19%)
Jun 2026 20.0× (52.79%)
Mar 2026 42.5× (24.26%)
Dec 2025 56.1× (15.35%)
27 more quarters

Against its own ten years

Low 0.0× High 98.1×
Ten-year median 13.4×
Current reading's percentile 42

EV/Sales against peers

Company EV/Sales
BNTX BioNTech SE Sponsored ADR compare 1.8×
INCY Incyte Corporation compare 3.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 3.7×
EXEL Exelixis, Inc. compare 6.5×
GMAB Genmab A/S Sponsored ADR compare 8.7×
ASND Ascendis Pharma A/S compare 13.1×
INSM Insmed, Inc. 15.4×
BBIO BridgeBio Pharma, Inc. compare 15.9×
ROIV Roivant Sciences Ltd. compare 3,061×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on INSM